R
Reprieve Cardiovascular
Health Tech & Medtech · Milford, United States · Founded 2018
Led by a seasoned management team with extensive experience in the medical device industry MoreLess
Reprieve Cardiovascular is a medical device company that develops and commercializes therapies for fluid management in patients suffering from acute decompensated heart failure (ADHF).
The company's core offering is a personalized decongestion management system that automates the management of a patient's fluid levels. This system is designed to enable clinicians to remove excess fluid from patients with ADHF safely and effectively.
Reprieve Cardiovascular operates in the cardiovascular medical device market, targeting a patient population of over 25 million individuals with heart failure globally. The company's business model is centered on the development and sale of its proprietary medical devices to hospitals and other healthcare facilities that treat acute heart failure.
Keywords: medical devices, acute decompensated heart failure, fluid management, cardiovascular, decongestion, therapies, healthcare, life sciences, medical equipment, healthtech
Company overview
Reprieve Cardiovascular company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2018
- Headquarters
- Milford, United States
- Employees
- 34
- Open positions
- None listed
- Dealroom signal
- 89.8
Valuation & funding
Reprieve Cardiovascular funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Aug 2025 | $61M | $244M | Arboretum Ventures · Rex Health Ventures · Genesis Capital · Sante Ventures | ↗ |
| SERIES AOther financing | Feb 2024 | $42M | $168M | Sante Ventures · Deerfield · Genesis Capital · Arboretum Ventures | ↗ |
| EARLY VCOther financing | Jun 2022 | $15M | $60M | Undisclosed | ↗ |
| EARLY VCOther financing | Aug 2020 | $15M | $60M | Undisclosed | — |
| EARLY VCOther financing | Sep 2018 | $7M | $28M | Abiomed | — |
Growth signals
Reprieve Cardiovascular website traffic
Latest recorded traffic for Reprieve Cardiovascular is 1.3K monthly website visits, down 35% over the last three months. Reprieve Cardiovascular's team grew 13.3% over the past year.
Comparisons
Reprieve Cardiovascular compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Reprieve Cardiovascular's talent
Source: Dealroom Talent Intelligence.
Investors
8 investors on Reprieve Cardiovascular's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Reprieve Cardiovascular has talent and traffic
team presence
In the news
Latest news about Reprieve Cardiovascular
Recent press, funding announcements, and product moves mentioning Reprieve Cardiovascular — open to read from the original sources.
Market sentiment
What the market is saying about Reprieve Cardiovascular
An AI-synthesized read of the highest-engagement posts about Reprieve Cardiovascular on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Reprieve Cardiovascular’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.